• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ramipril Plus Teva
    / Teva

    Active Ingredient *
    Hydrochlorothiazide 12.5 mg, 25 mg
    Ramipril 2.5 mg, 5 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 2.5 mg/12.5 mg

    partial basket chart 75226 18381


    30 X 5 mg/25 mg

    partial basket chart 75227 18382

    Related information


    Please contact distributor for full details.


    Essential hypertension in patients in whom blood pressure cannot be adequately lowered with ramipril alone.


    Hypersensitivty to active ingredients, any other ACE inhibitor, other thiazide diuretics, sulfonamides, or to any other ingredient of the preparation. History of angioneurotic edema. Severe renal impairment (creatinine clearance below 30 ml/min per 1.73 m2 body surface area, and in dialysis patients. Hemodynamically relevant left-ventricular inflow or outflow impediment (e.g. stenosis of the aortic or mitral valve). Clinically relevant electrolyte disturbances which may worsen following treatment with this product, e.g., hypokalemia,hyponatremia, or hypercalcemia. Severe liver function impairment. Pregnancy, lactation. Concomitant use of ACE inhibitors and extracorporeal treatments leading to contact of blood with negatively charged surfaces must be avoided, since sunch use may lead to severe anaphylactoid reactions. Such extracorporeal treatments include dialysis or hemofiltration with certain high-flux (e.g. polyacrylonitril) membranes and low-density lipoprotein apheresis with dextran sulfate.

    Special Precautions

    Please contact distributor for full details.

    Side Effects

    Please contact distributor for full details.

    Drug interactions